1
|
Tarride JE, Okoh A, Aryal K, Prada C, Milinkovic D, Keepanasseril A, Iorio A. Scoping review of the recommendations and guidance for improving the quality of rare disease registries. Orphanet J Rare Dis 2024; 19:187. [PMID: 38711103 PMCID: PMC11075280 DOI: 10.1186/s13023-024-03193-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Accepted: 04/19/2024] [Indexed: 05/08/2024] Open
Abstract
BACKGROUND Rare disease registries (RDRs) are valuable tools for improving clinical care and advancing research. However, they often vary qualitatively, structurally, and operationally in ways that can determine their potential utility as a source of evidence to support decision-making regarding the approval and funding of new treatments for rare diseases. OBJECTIVES The goal of this research project was to review the literature on rare disease registries and identify best practices to improve the quality of RDRs. METHODS In this scoping review, we searched MEDLINE and EMBASE as well as the websites of regulatory bodies and health technology assessment agencies from 2010 to April 2023 for literature offering guidance or recommendations to ensure, improve, or maintain quality RDRs. RESULTS The search yielded 1,175 unique references, of which 64 met the inclusion criteria. The characteristics of RDRs deemed to be relevant to their quality align with three main domains and several sub-domains considered to be best practices for quality RDRs: (1) governance (registry purpose and description; governance structure; stakeholder engagement; sustainability; ethics/legal/privacy; data governance; documentation; and training and support); (2) data (standardized disease classification; common data elements; data dictionary; data collection; data quality and assurance; and data analysis and reporting); and (3) information technology (IT) infrastructure (physical and virtual infrastructure; and software infrastructure guided by FAIR principles (Findability; Accessibility; Interoperability; and Reusability). CONCLUSIONS Although RDRs face numerous challenges due to their small and dispersed populations, RDRs can generate quality data to support healthcare decision-making through the use of standards and principles on strong governance, quality data practices, and IT infrastructure.
Collapse
Affiliation(s)
- J E Tarride
- Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada
- Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada
- Programs for the Assessment of Technologies in Health (PATH), The Research Institute of St. Joe's Hamilton, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - A Okoh
- Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada
| | - K Aryal
- Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada
| | - C Prada
- Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada
| | - Deborah Milinkovic
- Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
| | - A Keepanasseril
- Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada
| | - A Iorio
- Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada
| |
Collapse
|
2
|
Alves VM, Korn D, Pervitsky V, Thieme A, Capuzzi S, Baker N, Chirkova R, Ekins S, Muratov EN, Hickey A, Tropsha A. Knowledge-based approaches to drug discovery for rare diseases. Drug Discov Today 2022; 27:490-502. [PMID: 34718207 PMCID: PMC9124594 DOI: 10.1016/j.drudis.2021.10.014] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 09/13/2021] [Accepted: 10/21/2021] [Indexed: 02/03/2023]
Abstract
The conventional drug discovery pipeline has proven to be unsustainable for rare diseases. Herein, we discuss recent advances in biomedical knowledge mining applied to discovering therapeutics for rare diseases. We summarize current chemogenomics data of relevance to rare diseases and provide a perspective on the effectiveness of machine learning (ML) and biomedical knowledge graph mining in rare disease drug discovery. We illustrate the power of these methodologies using a chordoma case study. We expect that a broader application of knowledge graph mining and artificial intelligence (AI) approaches will expedite the discovery of viable drug candidates against both rare and common diseases.
Collapse
Affiliation(s)
- Vinicius M. Alves
- Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.,UNC Catalyst for Rare Diseases, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Daniel Korn
- Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Vera Pervitsky
- Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Andrew Thieme
- Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Stephen Capuzzi
- Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA
| | - Nancy Baker
- ParlezChem, 123 W Union Street, Hillsborough, NC, 27278, USA
| | - Rada Chirkova
- Department of Computer Science, North Carolina State University, Raleigh, NC, 27695-8206, USA
| | - Sean Ekins
- Collaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510 Raleigh, North Carolina 27606, USA
| | - Eugene N. Muratov
- Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.,Department of Pharmaceutical Sciences, Federal University of Paraiba, Joao Pessoa, PB, Brazil
| | - Anthony Hickey
- UNC Catalyst for Rare Diseases, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.,Corresponding Authors: Addresses for correspondence: Room 1079, 120 Mason Farm Rd, Genetics Medicine Building, University of North Carolina, Chapel Hill, NC 27514; Telephone: (919) 966-2955; FAX: (919) 966-0204; . 100K Beard Hall, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA; Telephone: (919) 966-2955; FAX: (919) 966-0204;
| | - Alexander Tropsha
- Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.,Corresponding Authors: Addresses for correspondence: Room 1079, 120 Mason Farm Rd, Genetics Medicine Building, University of North Carolina, Chapel Hill, NC 27514; Telephone: (919) 966-2955; FAX: (919) 966-0204; . 100K Beard Hall, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA; Telephone: (919) 966-2955; FAX: (919) 966-0204;
| |
Collapse
|
3
|
Bellgard MI, Snelling T, McGree JM. RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework. Orphanet J Rare Dis 2019; 14:176. [PMID: 31300021 PMCID: PMC6626403 DOI: 10.1186/s13023-019-1139-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Accepted: 06/21/2019] [Indexed: 12/18/2022] Open
Abstract
Within the 21 APEC economies alone, there are an estimated 200 million individuals living with a rare disease. As such, health data on these individuals, and hence patient registries, are vital. However, registries can come in many different forms and operating models in different jurisdictions. They possess a varying degree of functionality and are used for a variety of purposes. For instance registries can facilitate service planning as well as underpin public health and clinical research by providing de-identified data to researchers. Furthermore, registries may be used to create and disseminate new knowledge to inform clinical best practice and care, to identify and enrol participants for clinical trials, and to enable seamless integration of patient data for diagnostic testing and cascade screening. Registries that add capability such as capturing patient reported outcomes enable patients, and their carers, to become active partners in their care, rapidly furthering research and ensuring up-to-date practice-based evidence. Typically, a patient registry centres around the notion of health data 'capture', usually for only one or a small subset of the functions outlined above, thereby creating fragmented datasets that, despite the best efforts and intentions, make it difficult to exchange the right data for the right purpose to the right stakeholder under appropriate governance arrangements. Trying to incorporate maximum functionality into a registry is an obvious strategy, but monolithic software solutions are not desirable. As an alternative, we propose that it is important to incorporate analytics as core to a patient registry, rather than just utilising registries as a 'data capture' solution. We contend that embracing an analytics-centric focus makes it reasonable to imagine a future where it will be possible to evaluate the individual outcomes of health interventions in real time. The purposeful and, importantly, the repurposable application of health data will allow stakeholders to extract, create and reuse knowledge to improve health outcomes, assist clinical decision making, and improve health service design and delivery. To realise this vision, we introduce and describe the concept of a Rare Disease Registry and Analytics Platform (RD-RAP); one that we hope will make a meaningful difference to the lives of those living with a rare disease.
Collapse
Affiliation(s)
- Matthew I Bellgard
- Office of eResearch, Queensland University of Technology, Brisbane, 4000, Australia.
| | - Tom Snelling
- Wesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute, Perth, 6009, Australia
| | - James M McGree
- School of Mathematics, Queensland University of Technology, Brisbane, 4000, Australia
| |
Collapse
|
4
|
Bellgard MI, Chartres N, Watts GF, Wilton S, Fletcher S, Hunter A, Snelling T. Comprehending the Health Informatics Spectrum: Grappling with System Entropy and Advancing Quality Clinical Research. Front Public Health 2017; 5:224. [PMID: 28959687 PMCID: PMC5603612 DOI: 10.3389/fpubh.2017.00224] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Accepted: 08/08/2017] [Indexed: 12/30/2022] Open
Affiliation(s)
- Matthew I Bellgard
- Centre for Comparative Genomics, Murdoch University, Murdoch, WA, Australia
| | - Nigel Chartres
- Health Informatics Society of Australia, North Melbourne, VIC, Australia
| | - Gerald F Watts
- School of Medicine, University of Western Australia, Perth, WA, Australia.,Lipid Disorders Clinic, Cardiometabolic Service, Royal Perth Hospital, Perth, WA, Australia
| | - Steve Wilton
- Centre for Comparative Genomics, Murdoch University, Murdoch, WA, Australia.,Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia.,Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Sue Fletcher
- Centre for Comparative Genomics, Murdoch University, Murdoch, WA, Australia.,Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, WA, Australia.,Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Adam Hunter
- Centre for Comparative Genomics, Murdoch University, Murdoch, WA, Australia
| | - Tom Snelling
- Princess Margaret Hospital for Children, Perth, WA, Australia.,Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.,Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia
| |
Collapse
|
5
|
Bellgard MI, Walker CE, Napier KR, Lamont L, Hunter AA, Render L, Radochonski M, Pang J, Pedrotti A, Sullivan DR, Kostner K, Bishop W, George PM, O'Brien RC, Clifton PM, Bockxmeer FMV, Nicholls SJ, Hamilton-Craig I, Dawkins HJ, Watts GF. Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration. J Atheroscler Thromb 2017; 24:1075-1084. [PMID: 28344196 PMCID: PMC5656770 DOI: 10.5551/jat.37507] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Familial Hypercholesterolemia (FH) is the most common and serious monogenic disorder of lipoprotein metabolism that leads to premature coronary heart disease. There are over 65,000 people estimated to have FH in Australia, but many remain undiagnosed. Patients with FH are often undertreated, but with early detection, cascade family testing and adequate treatment, patient outcomes can improve. Patient registries are key tools for providing new information on FH and enhancing care worldwide. The development and design of the FH Australasia Network Registry is a crucial component in the comprehensive model of care for FH, which aims to provide a standardized, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes. Informed by stakeholder engagement, the FH Australasia Network Registry was collaboratively developed by government, patient and clinical networks and research groups. The open-source, webbased Rare Disease Registry Framework was the architecture chosen for this registry owing to its open-source standards, modular design, interoperability, scalability and security features; all these are key components required to meet the ever changing clinical demands across regions. This paper provides a high level blueprint for other countries and jurisdictions to help inform and map out the critical features of an FH registry to meet their particular health system needs.
Collapse
Affiliation(s)
| | - Caroline E Walker
- Office of Population Health Genomics, Public Health Division, Department of Health, Government of Western Australia
| | | | - Leanne Lamont
- Office of Population Health Genomics, Public Health Division, Department of Health, Government of Western Australia
| | - Adam A Hunter
- Centre for Comparative Genomics, Murdoch University, Murdoch
| | - Lee Render
- Centre for Comparative Genomics, Murdoch University, Murdoch
| | | | - Jing Pang
- School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia
| | - Annette Pedrotti
- Familial Hypercholesterolaemia Family Support Group of Western Australia
| | | | | | - Warrick Bishop
- Menzies Institute for Medical Research, University of Tasmania
| | | | | | - Peter M Clifton
- School of Pharmacy and Medical Sciences, University of South Australia
| | - Frank M Van Bockxmeer
- Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital.,School of Surgery, University of Western Australia
| | - Stephen J Nicholls
- South Australian Health and Medical Research Institute, University of Adelaide
| | | | - Hugh Js Dawkins
- Centre for Comparative Genomics, Murdoch University, Murdoch.,Office of Population Health Genomics, Public Health Division, Department of Health, Government of Western Australia.,Centre for Population Health Research, Curtin University of Technology.,School of Pathology and Laboratory Medicine, University of Western Australia
| | - Gerald F Watts
- School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia.,Lipid Disorders Clinic, Cardiometabolic Service, Royal Perth Hospital
| |
Collapse
|
6
|
Badiu C, Bonomi M, Borshchevsky I, Cools M, Craen M, Ghervan C, Hauschild M, Hershkovitz E, Hrabovszky E, Juul A, Kim SH, Kumanov P, Lecumberri B, Lemos MC, Neocleous V, Niedziela M, Djurdjevic SP, Persani L, Phan-Hug F, Pignatelli D, Pitteloud N, Popovic V, Quinton R, Skordis N, Smith N, Stefanija MA, Xu C, Young J, Dwyer AA. Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism. Orphanet J Rare Dis 2017; 12:57. [PMID: 28320476 PMCID: PMC5359990 DOI: 10.1186/s13023-017-0608-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Accepted: 03/06/2017] [Indexed: 11/22/2022] Open
Abstract
Background Patients with rare diseases face health disparities and are often challenged to find accurate information about their condition. We aimed to use the best available evidence and community partnerships to produce patient education materials for congenital hypogonadotropic hypogonadism (CHH) and the olfacto-genital (Kallmann) syndrome (i.e., CHH and defective sense of smell), and to evaluate end-user acceptability. Expert clinicians, researchers and patients co-created the materials in a multi-step process. Six validated algorithms were used to assess reading level of the final product. Comprehensibility and actionability were measured using the Patient Education Materials Assessment Tool via web-based data collection. Descriptive statistics were employed to summarize data and thematic analysis for analyzing open-ended responses. Subsequently, translation and cultural adaption were conducted by clinicians and patients who are native speakers. Results Co-created patient education materials reached the target 6th grade reading level according to 2/6 (33%) algorithms (range: grade 5.9–9.7). The online survey received 164 hits in 2 months and 63/159 (40%) of eligible patients completed the evaluation. Patients ranged in age from 18 to 66 years (median 36, mean 39 ± 11) and 52/63 (83%), had adequate health literacy. Patients scored understandability at 94.2% and actionability at 90.5%. The patient education materials were culturally adapted and translated into 20 languages (available in Additional file 1). Conclusions Partnering with patients enabled us to create patient education materials that met patient- identified needs as evidenced by high end-user acceptability, understandability and actionability. The web-based evaluation was effective for reaching dispersed rare disease patients. Combining dissemination via traditional healthcare professional platforms as well as patient-centric sites can facilitate broad uptake of culturally adapted translations. This process may serve as a roadmap for creating patient education materials for other rare diseases. Electronic supplementary material The online version of this article (doi:10.1186/s13023-017-0608-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | - Corin Badiu
- Department of Endocrinology, National Institute of Endocrinology, C. Davila University of Medicine and Pharmacy, Bucharest, 050474, Romania
| | - Marco Bonomi
- Deptartment of Clinical Sciences & Community Health and the Division of Endocrine and Metabolic Diseases & Laboratory of Endocrine and Metabolic Research, University of Milan, Milan, Italy.,Ospedale San Luca, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, Italy
| | - Ivan Borshchevsky
- Patient Advocacy Working Group and the International Medical Interpreters Association, Pyatigorsk, Russia
| | - Martine Cools
- University Hospital Ghent Department of Pediatric Endocrinology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium
| | - Margarita Craen
- University Hospital Ghent Department of Pediatric Endocrinology, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium
| | - Cristina Ghervan
- University of Medicine and Pharmacy "Iuliu Hatieganu", 8, V Babes str., 400012, Cluj-Napoca, Romania
| | - Michael Hauschild
- Endocrinology, Diabetes & Obesity Service of the Department of Pediatric Medicine and Surgery, Children's Hospital of Lausanne, Chemin de Montétan 16, 1004, Lausanne, Switzerland
| | - Eli Hershkovitz
- Pediatric Endocrinology and Metabolism Unit, Faculty of Health Sciences, Soroka Medical Center, Ben-Gurion University of the Negev, PO Box 151, IL-84101, Beer-Sheva, Israel
| | - Erik Hrabovszky
- Laboratory of Endocrine Neurobiology of the Institute of Experimental Medicine of the Hungarian Academy of Sciences, 43 Szigony St., 1083, Budapest, Hungary
| | - Anders Juul
- Department of Growth and Reproduction GR, Rigshospitalet section 5064, Blegdamsvej 9, 2100, Copenhagen, Denmark
| | - Soo-Hyun Kim
- St. George's Medical School of the University of London, Molecular & Clinical Sciences Research Institute, Cell Biology & Genetics Research Centre, Cranmer Terrace, London, SW17 0RE, UK
| | - Phillip Kumanov
- Clinical Center of Endocrinology, Medical University, 2 Zdrawe St, 1431, Sofia, Bulgaria
| | - Beatriz Lecumberri
- Autónoma University of Madrid, Hospital La Paz Institute of Health Research (IdiPAZ), Endocrinology and Nutrition Service of La Paz University Hospital, Castellana 261, 28046, Madrid, Spain
| | - Manuel C Lemos
- CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilha, 6200-506, Portugal
| | - Vassos Neocleous
- Department of Molecular Genetics of the Cyprus Institute of Neurology and Genetics, P.O. Box 23462, Nicosia, Cyprus
| | - Marek Niedziela
- Department of Pediatric Endocrinology and Rheumatology, Poznan University of Medical Sciences, Szpitalna Street 27/33, 60-572, Poznan, Poland
| | - Sandra Pekic Djurdjevic
- School of Medicine, University of Belgrade & Clinic of Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center Belgrade, dr Subotic 13, 11000, Belgrade, Serbia
| | - Luca Persani
- Ospedale San Luca, IRCCS Istituto Auxologico Italiano, Piazzale Brescia 20, 20149, Milan, Italy.,Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy.,Division of Endocrine and Metabolic Diseases & Laboratory of Endocrine and Metabolic Research, Milan, Italy
| | - Franziska Phan-Hug
- Endocrinology, Diabetes & Obesity Service of the Department of Pediatric Medicine and Surgery, Children's Hospital of Lausanne, Chemin de Montétan 16, 1004, Lausanne, Switzerland
| | - Duarte Pignatelli
- Department of Endocrinology, Hospital S João, Alameda Hernani Monteiro, 4200, Porto, Portugal
| | - Nelly Pitteloud
- University of Lausanne and the Endocrinology, Diabetes & Metabolism Service, Lausanne University Hospital, Rue du Bugnon 46, Lausanne, 1011, Switzerland
| | - Vera Popovic
- School of Medicine, University of Belgrade, dr Subotic 8, 11000, Belgrade, Serbia
| | - Richard Quinton
- University of Newcastle-upon-Tyne, Institute of Genetic Medicine and the Royal Victoria Infirmary, Newcastle-upon-Tyne, NE1 3BZ, UK
| | - Nicos Skordis
- Division of Pediatric Endocrinology, Paedi Center for specialized Pediatrics, Nicosia, Cyprus.,St George's University of London Medical School at the University of Nicosia, Nicosia, Cyprus
| | - Neil Smith
- Patient Advocacy Working Group, London, UK
| | - Magdalena Avbelj Stefanija
- University Medical Centre Ljubljana, University Children's Hospital, Dept. of pediatric endocrinology, diabetes and metabolism, Bohoriceva ul. 20, 1000, Ljubljana, Slovenia
| | - Cheng Xu
- University of Lausanne and the Endocrinology, Diabetes & Metabolism Service, Lausanne University Hospital, Rue du Bugnon 46, Lausanne, 1011, Switzerland
| | - Jacques Young
- Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital Bicêtre, Le Kremlin-Bicêtre, 94275, France
| | - Andrew A Dwyer
- University of Lausanne, Institute of Higher Education & Research in Healthcare and the Endocrinology, Diabetes & Metabolism Service of the Lausanne University Hospital, Route de la Corniche 10, Lausanne, 1010, Switzerland.
| |
Collapse
|
7
|
Rubinstein YR, Posada de la Paz M, Mora M. Rare Disease Biospecimens and Patient Registries: Interoperability for Research Promotion, a European Example: EuroBioBank and SpainRDR-BioNER. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 1031:141-147. [PMID: 29214569 DOI: 10.1007/978-3-319-67144-4_7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Well-annotated and properly preserved specimens are crucial both for diagnostic purposes and for use in basic and pre-clinical research, and are especially important for rare disease (RD) studies. Several consortia have been established in the recent years in order to facilitate research and to maximise access to rare biological samples and data stored in rare disease biobanks and registries, among them the EuroBioBank network and the Spain National Rare Disease Registry (RDR) and Biobank (BioNER).EuroBioBank, established in 2001, was the first network of RD biobanks to operate in Europe as a service distributing human DNA, cells, and tissue to the scientific community conducting research on rare diseases.The Spanish RDR and BioNER were created for facilitating rare disease research and health-related matters. The coordination of these two bodies represents an example of great scientific value as biological samples donated by patients at BioNER are linked to clinical information collected in the RDR.Rare disease biobanks and registries will need for the future to increase their effort to improve interconnection so to enable investigators to better locate samples and associated data, while protecting security of the data and privacy of the participants and adhering to international ethical and legal requirements.
Collapse
Affiliation(s)
- Yaffa R Rubinstein
- National Information Center of Health Services Research & Health Care Technology, National Library of Medicine/National Institute of Health, Bethesda, MD, 20892-1851, USA.
| | | | - Marina Mora
- Neuromuscular and Neuroimmunology Unit, C. Besta Neurological Institute, Milan, Italy
| |
Collapse
|
8
|
Affiliation(s)
- Haotian Lin
- The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China
| | - Erping Long
- The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China
| | - Weirong Chen
- The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China
| | - Yizhi Liu
- The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510060, China.
| |
Collapse
|